Teprotumumab N01 + Methylprednisolone
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Thyroid Eye Disease
Conditions
Thyroid Eye Disease
Trial Timeline
Dec 30, 2025 → Sep 4, 2027
NCT ID
NCT07265258About Teprotumumab N01 + Methylprednisolone
Teprotumumab N01 + Methylprednisolone is a approved stage product being developed by Innovent Biologics for Thyroid Eye Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07265258. Target conditions include Thyroid Eye Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07265258 | Approved | Recruiting |
Competing Products
20 competing products in Thyroid Eye Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MBX 2109 | MBX Biosciences | Phase 2 | 47 |
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | 47 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | 41 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib + Placebo + Lenvatinib | Eisai | Phase 3 | 77 |
| Irofulven + capecitabine | Eisai | Phase 2 | 52 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 77 |
| Lenvatinib | Eisai | Approved | 85 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Bexarotene | Eisai | Phase 1 | 33 |
| Lenvatinib + Lenvatinib matching placebo | Eisai | Phase 2 | 52 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| E7080 capsule | Eisai | Phase 2 | 52 |
| Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort) | Eisai | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |